Gaad surveillance
Gaad surveillance has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 17, 2026: “Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data”.
1 paper studies it1 findingUpdated
See all 1 papers on gaad surveillance
- In silico1
What did studies of gaad surveillance find?
1Studies of gaad surveillance measured one outcome, quality-adjusted life-years.
Quality-adjusted life-years
upin silico1
1 study
Quality-adjusted life-years
upin silico1
Gaad surveillance improves quality-adjusted life-years in silico (simulated cohort of patients with compensated cirrhosis) (dominant vs US and US+AFP; US+GAAD ICUR €9,482 and €10,951 per QALY gained).
“Compared to US and US+AFP, GAAD was dominant, while US+GAAD was cost-effective (ICUR of €9,482 and €10,951 per QALY gained, respectively).”
In silicosimulated cohort of patients with compensated cirrhosisn = 100,000
Journal of medical economics